A news item in the Feb. 22, 2002, issue of BioWorld Today misspelled “Advexin,” Introgen Therapeutics Inc.’s trademarked name for the gene-based cancer drug formerly called INGN 210.

A story on cardiovascular drugs and devices in the Feb. 22, 2002, issue of BioWorld Today listed the wrong location for Emisphere Technologies Inc. The company is based in Tarrytown, N.Y.

Editor’s note: The corrections have been made in BioWorld Online.